Logo

American Heart Association

  20
  0


Final ID: Su2129

Exploring Optimal Cardiac Electronic Implantable Devices Programming: Reducing Non-Actionable Alerts and Assessing Clinical Outcomes

Abstract Body (Do not enter title and authors here): Background: Remote monitoring for cardiac electronic implantable devices (CIEDs) has become standard of care, resulting in an abundance of remote transmission data. While this data is valuable, the number of clinically irrelevant non-actionable alerts (NAA) can lead to alert fatigue and reduce device clinic efficiency.
Objective: We aimed to propose clinically reasonable alert parameters to reduce the number of NAA and explore its impact on clinical outcomes.
Methods: We included 412 participants with CIEDs indicated for atrial fibrillation (AF) or non-sustained ventricular tachycardia (NSVT) from a single academic medical center. Reprogramming changes set as no alerts for AF episodes < 5.5 hours, persistent AF episodes > 1 month when a prior alert has already been issued, AF episodes < 24 hours in patients with paroxysmal AF on anticoagulation or with left atrial appendage occlusion, NSVT in patients with defibrillators. The number of NAAs were tracked 90 days before and after reprogramming. Incident ischemic stroke and sudden cardiac death (SCD) was ascertained over a median follow-up of 20.9 months. Linear regression was used to compare differences in alarms between pre- and post-periods, and multivariable linear regression was applied to identify factors associated with alerts.
Results: Among participants, indication for reprogramming included 69% (n=285) patients with AF and 30.7% (n=127) with NSVT. Compared to pre-programming, the number of NAAs was significantly lower post reprogramming implementation (median [IQR]: 3 [6] vs. 1 [2], P < 0.001) respectively. During follow up, the incidence of primary outcomes was 3.6% (n:15) for ischemic stroke and 0.7% (n=3) for SCD. (Table)
Conclusion: Our findings demonstrate that implementing guidelines-derived alert parameters in patients with CIEDs significantly reduces the number of clinically irrelevant NAA. This reduction in NAA appears to be safe, with incidence of adverse clinical outcomes comparable to the general population of patients with CIED. This approach has the potential toreduce clinician alert fatigue and safely improve efficiency of device clinics.
  • Mostafa, Mohamed  ( Wake Forest School of Medicine , Winston Salem , North Carolina , United States )
  • Bodziock, George  ( Wake Forest School of Medicine , Winston Salem , North Carolina , United States )
  • Seiler, Amber  ( CV Remote Solutions , Greensporo , North Carolina , United States )
  • Dillon, John  ( Wake Forest School of Medicine , Winston Salem , North Carolina , United States )
  • Cotten, Lindsey  ( CV Remote Solutions , Greensporo , North Carolina , United States )
  • Allred, James  ( CV Remote Solutions , Greensporo , North Carolina , United States )
  • Bhave, Prashant  ( Wake Forest School of Medicine , Winston Salem , North Carolina , United States )
  • Author Disclosures:
    Mohamed Mostafa: DO NOT have relevant financial relationships | George Bodziock: DO NOT have relevant financial relationships | Amber Seiler: DO have relevant financial relationships ; Ownership Interest:CV Remote Solutions:Active (exists now) ; Speaker:Medtronic:Active (exists now) | John Dillon: No Answer | Lindsey Cotten: DO NOT have relevant financial relationships | James Allred: DO have relevant financial relationships ; Ownership Interest:CV Remote Solutions:Active (exists now) | Prashant Bhave: DO have relevant financial relationships ; Consultant:Medtronic:Past (completed) ; Consultant:Alta Thera:Past (completed) ; Speaker:Boston Scientific:Past (completed) ; Speaker:Abbott:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Improvements in Cardiac Implantable Electronic Device Therapies

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy

Sapp John, Roux Jean-francois, Nery Pablo, Nault Isabelle, Amit Guy, Raymond Jean-marc, Deyell Marc, Sacher Frederic, De Chillou Christian, Kuriachan Vikas, Abdelwahab Amir, Tang Anthony, Sarrazin Jean-francois, Dyrda Katia, Sikkel Markus, Wilton Stephen, Jolly Umjeet, Kanagasundram Arvindh, Wells George, Parkash Ratika, Stevenson William, Healey Jeff, Gula Lorne, Nair Girish, Essebag Vidal, Rivard Lena

A pharmacovigilance investigation from the FAERS database on patients using pembrolizumab and its association with cardiac arrhythmias

Upreti Prakash, Jancic Predrag, Milutinovic Stefan, Rathore Azeem, Nassar Sameh, Karki Roshan, Rao Mohan, Patel Brijesh

More abstracts from these authors:
APOL1 Risk Variants and Risk of Incident Atrial Fibrillation in Systolic Blood Pressure Intervention Trial (SPRINT)

Ahmad Muhammad, Kazibwe Richard, Mostafa Mohamed, Naeem Rimsha, Singh Sanjay, Bansal Nisha, Soliman Elsayed

You have to be authorized to contact abstract author. Please, Login
Not Available